U.S., Dec. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07257861) titled 'Interest of Continuous Subcutaneous Apomorphine in Parkinsonian Patients at the End of Life' on Sept. 18.
Brief Summary: Care for Parkinson's patients at the end of life is far from optimal, particularly due to specificities linked to the disease itself, often unknown to non-specialists.
A study carried out at the CHU Rennes on data covering the period 2006-2018 showed that only 132 patients died in this hospital, two-thirds of whom came from home. In 42% of cases, antiparkinsonian treatment was stopped before death without specialist advice (palliative or neurological), with the corollary of the appearance of a dopaminergic withdra...